GSK Canada & Pan-Canadian Pharmaceutical Alliance Sign LOI For Blenrep For A Type Of Multiple Myeloma
Sept 22 (Reuters) - GSK Canada:
GSK CANADA AND THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE SIGN LETTER OF INTENT FOR BLENREP FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA
GSK CANADA: PATIENTS TO GAIN PUBLICLY FUNDED ACCESS TO BLENREP AS TREATMENT OPTION FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
Further company coverage: GSK.L